Traders Sell Shares of Eli Lilly And Co (LLY) on Strength (LLY)

Investors sold shares of Eli Lilly And Co (NYSE:LLY) on strength during trading hours on Monday. $75.31 million flowed into the stock on the tick-up and $107.70 million flowed out of the stock on the tick-down, for a money net flow of $32.39 million out of the stock. Of all companies tracked, Eli Lilly And Co had the 33rd highest net out-flow for the day. Eli Lilly And Co traded up $1.02 for the day and closed at $124.08

Several analysts have issued reports on LLY shares. Zacks Investment Research downgraded shares of Eli Lilly And Co from a “buy” rating to a “hold” rating in a research report on Tuesday, December 18th. BMO Capital Markets reissued a “buy” rating on shares of Eli Lilly And Co in a research report on Wednesday, December 19th. Morgan Stanley set a $116.00 price target on shares of Eli Lilly And Co and gave the stock a “hold” rating in a research report on Thursday, December 20th. Argus reissued a “buy” rating on shares of Eli Lilly And Co in a research report on Thursday, December 27th. Finally, Barclays reissued a “buy” rating and set a $130.00 price target on shares of Eli Lilly And Co in a research report on Sunday, January 20th. Ten research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $118.02.

The firm has a market capitalization of $128.52 billion, a P/E ratio of 20.99, a price-to-earnings-growth ratio of 2.35 and a beta of 0.33. The company has a current ratio of 1.73, a quick ratio of 1.38 and a debt-to-equity ratio of 1.07.

Eli Lilly And Co (NYSE:LLY) last released its quarterly earnings data on Wednesday, February 6th. The company reported $1.33 EPS for the quarter, missing analysts’ consensus estimates of $1.36 by ($0.03). The business had revenue of $6.44 billion during the quarter, compared to analyst estimates of $6.28 billion. Eli Lilly And Co had a return on equity of 44.66% and a net margin of 13.16%. The business’s revenue for the quarter was up 4.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.14 EPS. As a group, research analysts predict that Eli Lilly And Co will post 5.66 earnings per share for the current fiscal year.

In other Eli Lilly And Co news, SVP Alfonso G. Zulueta sold 4,000 shares of Eli Lilly And Co stock in a transaction on Thursday, January 31st. The shares were sold at an average price of $120.00, for a total value of $480,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Lilly Endowment Inc sold 205,000 shares of Eli Lilly And Co stock in a transaction on Tuesday, March 26th. The stock was sold at an average price of $131.41, for a total transaction of $26,939,050.00. Following the completion of the transaction, the insider now directly owns 116,814,018 shares of the company’s stock, valued at approximately $15,350,530,105.38. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,003,959 shares of company stock valued at $125,426,338. 0.11% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently added to or reduced their stakes in LLY. Rosenbaum Jay D. bought a new stake in Eli Lilly And Co in the first quarter valued at $208,000. Carroll Financial Associates Inc. lifted its stake in Eli Lilly And Co by 48.2% in the first quarter. Carroll Financial Associates Inc. now owns 10,419 shares of the company’s stock valued at $1,351,000 after buying an additional 3,390 shares during the last quarter. Chesapeake Wealth Management lifted its stake in Eli Lilly And Co by 28.9% in the first quarter. Chesapeake Wealth Management now owns 14,720 shares of the company’s stock valued at $1,910,000 after buying an additional 3,297 shares during the last quarter. City Holding Co. lifted its stake in Eli Lilly And Co by 1.5% in the first quarter. City Holding Co. now owns 35,325 shares of the company’s stock valued at $4,583,000 after buying an additional 535 shares during the last quarter. Finally, Tompkins Financial Corp lifted its stake in Eli Lilly And Co by 1.9% in the first quarter. Tompkins Financial Corp now owns 36,900 shares of the company’s stock valued at $3,960,000 after buying an additional 705 shares during the last quarter. 79.58% of the stock is owned by hedge funds and other institutional investors.

WARNING: “Traders Sell Shares of Eli Lilly And Co (LLY) on Strength (LLY)” was published by Markets Daily and is the sole property of of Markets Daily. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States and international copyright laws. The original version of this piece can be accessed at https://www.themarketsdaily.com/2019/04/18/traders-sell-shares-of-eli-lilly-and-co-lly-on-strength-lly.html.

Eli Lilly And Co Company Profile (NYSE:LLY)

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Read More: Asset Allocation

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.